Profile of Potential Drug Interactions in Chronic Obstructive Pulmonary Disease Patients in One of the Jember District Hospitals

Dea Agita Anggraini; Shinta Mayasari

Authors

Dea Agita Anggraini Faculty of Health Sciences, University of Dr. Soebandi, Jl. Dr. Soebandi no 99, Jember, Indonesia
Shinta Mayasari Faculty of Health Sciences, University of Dr. Soebandi, Jl. Dr. Soebandi no 99, Jember, Indonesia

Keywords:

Chronic obstructive pulmonary disease; Drug interactions; Hospitals; Drug interaction checker.

Abstract

Background: Chronic Obstructive Pulmonary Disease or often abbreviated as COPD is a term used for a number of non-communicable diseases that affect the lungs for the long term. COPD is the third leading cause of death in the world. The use of drugs in COPD patients with or without comorbidities is included in the category of drug use with more than two drug items, resulting in one of the DRPs, one of which is drug interaction. The prevalence of patients with potential drug interactions in Ethiopian hospitals was found to be 72.2%. The number of COPD cases is projected to increase by 112 million to a total of 592 million by 2050 (9.5% of the total eligible population), a relative increase of 23.3% from 2020 to 2050. Purpose: The purpose of this study was to determine the study of drug interactions in patients with Chronic Obstructive Pulmonary Disease at the Jember Pulmonary Hospital. Methods: This type of research is qualitative research using the observation method, retrospective data collection taken from medical record data of COPD patients. The number of samples in this study was 96 patients calculated using the Slovin formula. The sampling technique used was random sampling technique. Data were processed using Microsoft Excel and displayed in the form of frequencies and percentages. Conclusion: Potential drug interactions in COPD patients that occurred in one of the Jember Regency hospitals amounted to 97.92% using drug interaction checker with details of minor interaction categories 26,48%, moderate 68,80% and major 4,72%. Monitoring the occurrence of potential drug interactions is carried out in order to minimize the risk of drug side effects. Complaints of potential interactions in patients do not occur which can be seen from clinical manifestations in patients. The limitation of this study is that it does not know the patient's complaints directly because it only uses medical record data.

References

Astriani et al., 2021. Pendampingan Pelatihan Perkusi Dada. 2021;3(2):18 –23.

Boers et al., 2023. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. JAMA Netw Open. 2023;6(12):E2346598.

André et al., 2019. COPD and Cardiovascular Disease. Pulmonology. 2019 May 1;25(3):168–76..

Antariksa, 2020. Pedoman Diagnosis Dan Penatalaksanaan Di Indonesia . Penyakit Paru Obstruktif Kronik. Catalysis from A to Z. 2020;

Li L, Han Y, Zhang Z, … WZDD, 2021 U. Chronic Obstructive Pulmonary Disease Treatment and Pharmacist-Led Medication Management. NcbiNlmNihGov [Internet]. 2021;111–24. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811374/

Sari, Diah. Mayasari, Shinta, “PROFIL POTENSI INTERAKSI OBAT PADA PASIEN,” vol. 8, no. 2, pp. 115–127, 2025

Saftarina. Penatalaksanaan Penyakit Paru Obstruktif Kronis pada Pasien Laki-Laki Usia 66 Tahun Riwayat Perokok Aktif dengan Pendekatan Kedokteran Keluarga di Kecamatan Tanjung Sari Natar. Vol. 4. 2019.

Ayenew W, Asmamaw G, Issa A. Prevalence of potential drug-drug interactions and associated factors among outpatients and inpatients in Ethiopian hospitals: A systematic review and meta-analysis of observational studies. BMC Pharmacol Toxicol. 2020 Aug 24;21(1).

Untuk Memenuhi Persyaratan Gelar Sarjana Farmasi D. POTENSI HIPOGLIKEMIA PADA PASIEN DIABETES MELITUS TIPE 2 AKIBAT INTERAKSI OBAT DI RUMAH SAKIT CITRA HUSADA SKRIPSI. 2024.

Timban I, Langi FFLG, Kaunang WPJ, Kesehatan F, Universitas M, Abstrak SR, et al. DETERMINAN MEROKOK DI INDONESIA ANALISIS SURVEI DEMOGRAFI DAN KESEHATAN INDONESIA TAHUN 2012. Vol. 7, Jurnal KESMAS. 2020.

Ummah MS. IDENTIFIKASI POTENSI INTERAKSI OBAT PADA PASIEN PENYAKIT PARU OBSTRUKSI KRONIK DI INSTALASI RAWAT INAP RSUD BUDHI ASIH TAHUN 2017. Sustainability (Switzerland) [Internet]. 2019;11(1):1–14. Available from: http://scioteca.caf.com/bitstream/handle/123456789/1091/RED2017-Eng-8ene.pdf?sequence=12&isAllowed=y%0Ahttp://dx.doi.org/10.1016/j.regsciurbeco.2008.06.005%0Ahttps://www.researchgate.net/publication/305320484_SISTEM_PEMBETUNGAN_TERPUSAT_STRATEGI_MELESTARI

O DE, Kathryn Milne Matthew D James Juan Pablo de Torres J Alberto Neder DM. Dyspnea in COPD: New Mechanistic Insights and Management Implications. 2019; Available from: https://doi.org/10.6084/

Khairani R, Qalbiyah S. KORELASI SESAK NAPAS DENGAN OBSTRUKSI SALURAN NAPAS PADA PASIEN PENYAKIT PARU OBSTRUKTIF KRONIK. JURNAL PENELITIAN DAN KARYA ILMIAH LEMBAGA PENELITIAN UNIVERSITAS TRISAKTI. 2022 Jan 31;7(1):154–63.

Restrepo MI, Sibila O, Anzueto A. Pneumonia in patients with chronic obstructive pulmonary disease. Vol. 81, Tuberculosis and Respiratory Diseases. Korean National Tuberculosis Association; 2018. p. 187–97.

Sari CP, Hanifah S, Rosdiana R, Anisa Y. Efektivitas Pengobatan pada Pasien Penyakit Paru Obstruksi Kronis (PPOK) di Rumah Sakit Wilayah Yogyakarta. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice). 2021 Dec 31;11(4):215.

Ejiofor S, Turner AM. Pharmacotherapies for COPD. Vol. 7, Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine. 2013. p. 17–34.

Hazrina A, Wicaksono A. REVIEW ARTIKEL: TERAPI OBAT KOMBINASI ASMA BRONKIAL PADA PASIEN DEWASA. 2023.

Penelitian A, Dewi IP, Septiandini L, Merdeka Putri A, Fajrin A. Penggunaan Bronkodilator Tunggal atau Bersama Kortikosteroid dapat Memperbaiki Parameter Sesak, w/h, dan r/h pada Pasien Rawat Inap dengan PPOK Eksaserbasi Akut di RS.X di Jember Tahun 2018. 2022;11(3):198–208. Available from: http://ijcp.or.id

Poole PJ. Role of mucolytics in the management of COPD. International Journal of COPD. 2019.

Pengobatan Pada Pasien E, Rahmat J, Oktianti D. Evaluasi Pengobatan pada Pasien Penyakit Paru Obstruksi Kronis (PPOK) di RST Dr. Asmir Salatiga. Vol. 5, Journal of Holistics and Health Sciences. 2023.

Dr . Apt . Diana Laila Ramatillah M. F. Dr . Apt . Diana Laila Ramatillah , M . Farm Fakultas Farmasi Universitas 17 Agustus 1945 Jakarta. 1945;1–67.

Lorensia A, Ikawati Z, Andayani TM, Maranatha D, Amalia R. Membandingkan Kejadian Gangguan Gastrointestinal Penggunaan Aminofilin dan Salbutamol pada Pasien Eksaserbasi Asma di Surabaya. KELUWIH: Jurnal Kesehatan dan Kedokteran. 2019 Dec 17;1(1):1–10.

Ningrum et. al. Studi Potensi Interaksi Obat Pasien Covid-19 di Rumah Sakit Umum Daerah Mataram. 2023.

Ajimura CM, Jagan N, Morrow LE, Malesker MA. Drug Interactions With Oral Inhaled Medications. Vol. 34, Journal of Pharmacy Technology. SAGE Publications Inc.; 2018. p. 273–80.

Hanutami et. al. Identifikasi Potensi Interaksi Antar Obat Pada Resep Umum Di Apotek Kimia Farma 58 Kota Bandung Bulan April 2019. 2019;